ERBB3 and pancreatic neoplasm: Canertinib and afatinib treated pancreatic cancer cells showed a decrease in phosphorylation of EGFR at tyrosine 1068, HER2 at tyrosine 1248 and HER3 at tyrosine 1289 residues in pancreatic cancer cells at 5 and 1μM concentration respectively.